Carfilzomib - the selective proteasome inhibitor, the further expectation for the patients with the multiple myeloma
2016
Abstract
The introduction of "new drugs" in the treatment of multiple myeloma (MM) significantly improved the prognosis of patients, especially of those who can't undergo high-dose chemotherapy followed by autotransplantation of stem cells. One of the representatives of the new generation is carfilzomib.
It is a selective proteasome inhibitor whose use is indicated for patients with relapsed or refractory disease. In this case, it is clearly one of the most effective drugs, which was tested in MM patients so far.
The aim of this article is to familiarize readers with the profile of this drug, both its pharmacological properties, and also past experience gained with its use.